![PRD_002394 PRD_002394](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002394.svg) | PRD_002394 | Name: | UAW248 | Formula: | C30 H45 N5 O7 | Definition date: | 2020-06-17 | Last modified: | 2023-11-03 |
|
![PRD_000814 PRD_000814](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000814.svg) | PRD_000814 | Name: | N-{[(3R,4R,7S,10R,11R)-3-ethyl-11,15-dihydroxy-3-methyl-10-(methylamino)-6,9-dioxo-7-(propan-2-yl)-2-oxa-5,8-diazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-4-yl]carbonyl}glycine | Formula: | C23 H34 N4 O8 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000823 PRD_000823](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000823.svg) | PRD_000823 | Name: | N-propanoyl-D-alanyl-(4R)-4-[(7-bromoisoquinolin-1-yl)oxy]-N-{(1R,2R)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-L-prolinamide | Formula: | C29 H34 Br N5 O7 S | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000842 PRD_000842](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000842.svg) | PRD_000842 | Name: | PTA-SFTI INHIBITOR | Formula: | C66 H106 N20 O18 S2 | Description: | Bowman-Birk Inhibitor | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000845 PRD_000845](https://data.pdbj.org/pdbjplus/data/cc/svg/L4T.svg) | PRD_000845 | Name: | N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-7-methoxy-2-{2-[(2-methylpropanoyl)amino]-1,3-thiazol-4-yl}quinolin-4-yl)oxy]-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-L-prolinamide | Formula: | C40 H49 Br N6 O9 S | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000846 PRD_000846](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000846.svg) | PRD_000846 | Name: | TRYPSIN INHIBITOR 1 | Formula: | C66 H106 N20 O18 S2 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000849 PRD_000849](https://data.pdbj.org/pdbjplus/data/cc/svg/L5T.svg) | PRD_000849 | Name: | N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-{2-[(2-methylpropanoyl)amino]-1,3-thiazol-4-yl}quinolin-4-yl)oxy]-L-prolinamide | Formula: | C40 H50 N6 O9 S | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000857 PRD_000857](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000857.svg) | PRD_000857 | Name: | SAH-p53-8 stapled-peptide | Formula: | C96 H151 N26 O25 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_002417 PRD_002417](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002417.svg) | PRD_002417 | Name: | Ac-VRHA-conh-[4-(4-butyl)-phenoxy-1-phenyl-2-butyl] | Formula: | C43 H66 N10 O7 | Definition date: | 2023-10-25 | Last modified: | 2023-10-25 |
|
![PRD_002443 PRD_002443](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002443.svg) | PRD_002443 | Name: | SiaLac-amidine-Lys | Formula: | C33 H57 N5 O20 S | Definition date: | 2023-09-27 | Last modified: | 2023-09-27 |
|
![PRD_002387 PRD_002387](https://data.pdbj.org/pdbjplus/data/cc/svg/EJG.svg) | PRD_002387 | Name: | tert-butyl N-[5-phenyl-3-(2-phenylethylcarbamoyl)thiophen-2-yl]carbamate | Formula: | C24 H26 N2 O3 S | Definition date: | 2023-09-27 | Last modified: | 2023-09-27 |
|
![PRD_000020 PRD_000020](https://data.pdbj.org/pdbjplus/data/cc/svg/0G6.svg) | PRD_000020 | Name: | D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide | Formula: | C21 H34 Cl N6 O3 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000021 PRD_000021](https://data.pdbj.org/pdbjplus/data/cc/svg/0G7.svg) | PRD_000021 | Name: | D-phenylalanyl-N-[(3S)-6-carbamimidamido-1-chloro-2-oxohexan-3-yl]-L-prolinamide | Formula: | C21 H31 Cl N6 O3 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000102 PRD_000102](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000102.svg) | PRD_000102 | Name: | CYCLIC HEXAPEPTIDE RR(NAL)(NAL)RF | Formula: | C53 H70 N15 O6 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000103 PRD_000103](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000103.svg) | PRD_000103 | Name: | CYCLIC HEXAPEPTIDE KKWWKF | Formula: | C49 H68 N11 O6 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000104 PRD_000104](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000104.svg) | PRD_000104 | Name: | CYCLIC HEXAPEPTIDE RRYYRF | Formula: | C45 H66 N15 O8 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000105 PRD_000105](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000105.svg) | PRD_000105 | Name: | CYCLIC HEXAPEPTIDE CYC-(RRWWRF) | Formula: | C49 H68 N17 O6 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000106 PRD_000106](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000106.svg) | PRD_000106 | Name: | BOC-(D-NLE-L-NLE)4-D-NLE(METHYL)-L-NLE-D-NLE-L-NLE METHYL ESTER | Formula: | C79 H146 N12 O15 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000107 PRD_000107](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000107.svg) | PRD_000107 | Name: | H-(L-TYR-D-TYR)4-LYS-OH | Formula: | C78 H87 N10 O18 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000108 PRD_000108](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000108.svg) | PRD_000108 | Name: | HCO-(D-NLE-L-NLE)3-D-MENLE-L-NLE-D-NLE-L-NLE-OME | Formula: | C63 H116 N10 O12 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000109 PRD_000109](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000109.svg) | PRD_000109 | Name: | BOC-L-NLE-(D-NLE-L-NLE)5-D-NLE(METHYL)-L-NLE-D-NLE-L-NLE METHYL ESTER | Formula: | C96 H177 N15 O18 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000110 PRD_000110](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000110.svg) | PRD_000110 | Name: | DLY-HGL-AGD-LHC-AGD-LHC-CUD-LYS | Formula: | C60 H81 N34 O15 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000117 PRD_000117](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000117.svg) | PRD_000117 | Name: | ARYLOMYCIN A2 | Formula: | C42 H60 N6 O11 | Description: | ARYLOMYCIN A2 IS A BIARYL-BRIDGED LIPOPEPTIDE. THE SCAFFOLD IS MADE OF TWO PARTS: (1) N-TERM EXOCYCLIC TRIPEPTIDE (2)
A TRICYCLIC PEPTIDE, WITH [3,3] BIARYL BOND BETWEEN RESIDUE 4 AND 6 AN ISO-C12 FATTY ACID IS LINKED TO RESIDUE 1. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000142 PRD_000142](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000142.svg) | PRD_000142 | Name: | Cyclosporin A | Formula: | C62 H111 N11 O12 | Description: | CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE.
CYCLIZATION IS ACHIEVED BY LINKING THE N- AND
THE C- TERMINI. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000143 PRD_000143](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000143.svg) | PRD_000143 | Name: | Cyclosporin D | Formula: | C64 H115 N11 O12 S | Description: | CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE.
CYCLIZATION IS ACHIEVED BY LINKING THE N- AND
THE C- TERMINI.
CYCLOSPORIN D IS A NATURAL ANALOG OF CYCLOSPORIN A,
OBTAINED FROM A DIFFERENT NUTRIENT BROTH AND
DIFFERS FROM CYCLOSPORIN IN RESIDUE 6 (ABA6VAL). | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|